Skip to main content
CNMDCONMED CorporationSell5.3·$36.30-1.63%
Open full analysis

CONMED Corporation (CNMD) Stock Analysis

Recovery setup

SellModerate Confidence

Healthcare · Medical Devices

Sell if holding. Analyst target reached at $36.30 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3).

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture... Read more

$36.30+3.9% A.UpsideScore 5.3/10#23 of 40 Medical Devices
QualityF-score7 / 9FCF yield11.33%
IncomeYield2.17%(5y avg 1.02%)Payout22.60%sustainable
Stop $33.76Target $37.72(resistance)A.R:R -0.4:1
Analyst target$39.60+9.1%5 analysts
$37.72our TP
$36.30price
$39.60mean
$40

Sell if holding. Analyst target reached at $36.30 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: Death cross but MACD improving, RSI 47. Score 5.3/10, moderate confidence.

Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-11
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Aug 5, 202656d to earnings· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Attractive valuation
Risks
Analyst target reached - limited upside remaining
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
Below 200-MA, MA slope -5.2%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)20.8
P/E (Fwd)7.7
Mkt Cap$1.1B
EV/EBITDA9.2
Profit Mgn4.0%
ROE5.5%
Rev Growth-1.3%
Beta0.92
Dividend2.17%
Rating analysts11

Quality Signals

Piotroski F7/9

Options Flow

P/C5.00bearish
IV63%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
2.0
Support Resistance
3.4
Bollinger
3.6

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.8
Quality Rank
3.8
Value Rank
8.2
GatesA.R:R -0.4=NEGATIVEDeath cross (50MA < 200MA)Momentum 4.6<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.6>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 56d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
47 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $32.13Resistance $38.49

Price Targets

$34
$38
A.Upside+3.9%
A.R:R-0.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Target reached (-5.1% upside)
! Negative risk/reward — downside exceeds upside
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-05 (56d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CNMD stock a buy right now?

Sell if holding. Analyst target reached at $36.30 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: Death cross but MACD improving, RSI 47. Prior stop was $33.76. Score 5.3/10, moderate confidence.

What is the CNMD stock price target?

Take-profit target: $37.72 (+3.9% upside). Prior stop was $33.76. Stop-loss: $33.76.

What are the risks of investing in CNMD?

Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3); Below 200-MA, MA slope -5.2%/30d (confirmed downtrend).

Is CNMD overvalued or undervalued?

CONMED Corporation trades at a P/E of 20.8 (forward 7.7). TrendMatrix value score: 7.7/10. Verdict: Sell.

What do analysts say about CNMD?

11 analysts cover CNMD with a consensus score of 2.5/5. Average price target: $40.

What does CONMED Corporation do?CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical...

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Related stocks: PODD (Insulet Corporation) · LIVN (LivaNova PLC) · AORT (Artivion, Inc.) · MASI (Masimo Corporation) · ATEC (Alphatec Holdings, Inc.)
Home Stocks CNMD

Latest news

Latest News

Quiver Quantitative47d agoEarnings
Yahoo Finance47d ago
StockStory47d ago
Marketscreener.com47d agoEarnings
Cổng thông tin điện tử Tỉnh Sơn La54d ago
MarketBeat54d agoEarnings
Cổng thông tin điện tử tỉnh Lào Cai55d ago
MSN48d ago
Yahoo Finance48d agoEarnings
StockStory49d agoEarnings
TradingView49d agoEarnings
Cổng thông tin điện tử tỉnh Lào Cai54d agoEarnings
MarketBeat57d ago
Benzinga28d agoAnalyst
Benzinga45d agoAnalyst
Benzinga46d agoAnalyst
Benzinga47d agoEarnings
Benzinga47d ago
Benzinga47d agoEarnings